IQVIA Q1 2025 results show steady revenue growth, tighter EBITDA losses, and a robust cash balance as the company expands precision‑medicine and digital‑health partnerships and AI‑driven data analytics.
IQVIA reports a strong Q4 2026 earnings surge, with EPS of $3.26 and revenue up 6.5%, driving a 2026 outlook of $12.94 EPS and $17.4 billion revenue driven by data‑science‑powered clinical research and precision therapeutics.